PRESS RELEASE published on 07/24/2026 at 07:00, 2 months 15 days ago Ipsen provides update on Phase III BOLD trial in biliary atresia Ipsen's Phase III BOLD trial for biliary atresia did not meet primary endpoint. Bylvay safety profile confirmed. Insights gained will aid future research and patient care Ipsen Biliary Atresia Phase III BOLD Trial Bylvay Pediatric Liver Transplant
BRIEF published on 07/09/2026 at 07:05, 2 months 30 days ago Positive Phase III Results for Dysport® in the Treatment of Migraine Phase III Dysport Episodic Migraine Chronic Migraine Botulinum Toxin
BRIEF published on 07/09/2026 at 07:05, 2 months 30 days ago Dysport® Achieves Milestone in Migraine Phase III Trials Phase III Trials Dysport Episodic Migraine Chronic Migraine Botulinum Toxin
PRESS RELEASE published on 07/09/2026 at 07:00, 2 months 30 days ago Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine. Dysport® achieves positive topline Phase III results in both episodic and chronic migraine, marking a significant advancement in migraine treatment Prevention Dysport® Botulinum Toxin Phase III Results Migraine
BRIEF published on 07/06/2026 at 12:02, 3 months 2 days ago BlackRock's stake in IPSEN SA fluctuates at the 5% threshold. Share Capital Voting Rights BlackRock Threshold Crossing Ipsen SA
BRIEF published on 06/29/2026 at 07:05, 3 months 9 days ago Ipsen to Acquire Kartos Therapeutics, Enhancing Hemato-Oncology Portfolio Hemato-oncology Ipsen Acquisition Ruxolitinib Myelofibrosis Navtemadlin
PRESS RELEASE published on 06/29/2026 at 07:00, 3 months 9 days ago Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline Ipsen acquires Kartos Therapeutics, adding navtemadlin, a late-stage rare blood cancer asset in Phase III, to expand its Oncology portfolio. Top-line data from Phase III trial expected in 2027 Phase III Ipsen Hemato-oncology Navtemadlin Kartos Therapeutics
BRIEF published on 05/18/2026 at 07:05, 4 months 21 days ago Ipsen Initiates New Share Buy-back Program Share Buy-back Shareholder Value Investment Strategy Employee Share Plans Euronext: IPN
PRESS RELEASE published on 05/18/2026 at 07:00, 4 months 21 days ago Ipsen initiates a new share buy-back program Ipsen initiates new share buy-back program to purchase up to 350,000 shares, representing 0.42% of share capital. Program authorized by Annual General Meeting Share Buy-back Program Investment AGM Ipsen Employee Share-allocation
BRIEF published on 04/03/2026 at 07:05, 6 months 5 days ago Beech Tree Gains Exemption from Public Tender Offer for Ipsen Financial Markets Authority Ipsen Beech Tree Alasol Foundation Tender Offer Exemption
Published on 10/08/2026 at 22:05, 7 hours 18 minutes ago Rochon Family Executes Additional Strategic Purchase of $26.8 Million of AIAI Holdings Shares
Published on 10/08/2026 at 20:30, 8 hours 53 minutes ago Guanajuato Silver Completes San Ignacio to Bolanitos Connection Tunnel
Published on 10/08/2026 at 14:31, 14 hours 52 minutes ago First Breach Expands Hiring Initiative to Support Ammunition Production Growth and Planned Drone Manufacturing Operations
Published on 10/08/2026 at 14:30, 14 hours 53 minutes ago Predictiv AI's Shift AI Completes AWS Foundational Technical Review and Expands Aviation Visibility Through AWS Solutions Library
Published on 10/08/2026 at 14:00, 15 hours 23 minutes ago Earthwise Minerals Appoints Andy Randell, P.Geo., to Board of Directors
Published on 10/09/2026 at 03:00, 2 hours 22 minutes ago Partners Group launches new global multi-sector private credit income strategy
Published on 10/08/2026 at 20:10, 9 hours 13 minutes ago EQS-Adhoc: Westwing Group SE: Westwing Approves Share Buyback
Published on 10/08/2026 at 19:01, 10 hours 21 minutes ago LightOn releases LightOnOCR-3, a world-leading model family for document intelligence.
Published on 10/08/2026 at 18:30, 10 hours 53 minutes ago Form 8 (OPD) - Irish Residential Properties REIT plc
Published on 10/08/2026 at 18:00, 11 hours 23 minutes ago ROCTOOL: 2026 HALF-YEAR RESULTS - Stronger sales momentum and a promising second half of the year
Published on 10/08/2026 at 18:30, 10 hours 53 minutes ago Cegedim: Release of its 2026 Interim Financial Report
Published on 10/08/2026 at 18:00, 11 hours 23 minutes ago Launch of LINK, the next generation of THIN: Clinityx’s first European Health Data Warehouse, approved by the French Data Protection Authority for 10 years
Published on 10/08/2026 at 17:45, 11 hours 38 minutes ago Carrefour announces a real estate sale and leaseback transaction involving 35 stores in France and Spain
Published on 10/07/2026 at 18:19, 1 day 11 hours ago Outstanding shares and voting rights statement at 30 September 2026
